- PR Newswire•49 minutes ago
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "We believe romosozumab could serve as an important therapeutic option for osteoporosis patients with an increased risk of fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA, submitted on July 19, 2016, is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.
- TheStreet.com•2 hours ago
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||172.50 x 4000|
|Ask||173.75 x 5000|
|Day's Range||172.83 - 174.42|
|52wk Range||130.09 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.76|
|Avg Vol (3m)||2,864,382|
|Dividend & Yield||4.00 (2.29%)|